Numerous drugs containing a cationic amphiphilic structure are capable of inducing phospholipidosis in cells under conditions of in vivo administration or ex vivo incubation. The principal characteristics of this condition include the reversible accumulation of polar phospholipids in association with the development of unicentric or multicentric lamellated bodies within cells. There is an abundance of data providing an understanding of potential mechanisms for the induction of phospholipidosis; however, the process is likely to be complex and may differ from one drug to another. The functional consequences of the presence of this condition on cellular or tissue function are not well understood. The general consensus is that the condition is an adaptive response rather than a toxicological manifestation; however, additional studies to examine this question are needed. Until this issue is resolved, concerns about phospholipidosis will continue to exist at regulatory agencies. Procedures for the screening of potential phospholipogenic candidate compounds are available. In contrast, a clear need exists for the identification of valid biomarkers to assess the development of phospholipidosis in preclinical and clinical studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/14740338.5.4.567 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High Content Image Analysis of Cellular Responses of the Murine J774A.1 Cell Line and Primary Human Cells Alveolar Macrophages to an Extended Panel of Pharmaceutical Agents.
Pharm Res
January 2025
Department of Visceral, Transplant, Thoracic and Vascular Surgery, University of Leipzig Medical Center, 04103, Leipzig, Germany.
Introduction: In vitro screening of macrophages for drug-induced effects, such as phospholipidosis, is useful for detecting potentially problematic compounds in the preclinical development of oral inhaled products. High-content image analysis (HCIA) is a multi-parameter approach for cytotoxicity screening. This study provides new insights into HCIA-derived response patterns of murine J774A.
View Article and Find Full Text PDFCritical heart failure associated with beta-blocker-induced cardiac phospholipidosis: a case report.
Eur Heart J Case Rep
December 2024
Department of Cardiology, Tokyo Metropolitan Police Hospital, 4-22-1 Nakano, Nakano, Tokyo 164-8541, Japan.
Background: Drug-induced phospholipidosis (DIPL) is an acquired lysosomal storage disorder characterized by the accumulation of lamellar bodies and phospholipids, typically associated with the use of cationic amphiphilic drugs (CADs). Over 200 marketed CADs, including widely prescribed β-blockers, have the potential to induce phospholipid deposition in various organs. In rare cases, DIPL may lead to secondary cardiomyopathy.
View Article and Find Full Text PDFDogs with diet-associated dilated cardiomyopathy have higher urine di-docosahexaenoyl (22:6)-bis(monoacylglycerol)phosphate, a biomarker of phospholipidosis.
Am J Vet Res
January 2025
Department of Comparative Pathobiology, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA.
Objective: In dogs with diet-associated dilated cardiomyopathy (DCM), we have identified electron microscopic changes suggestive of abnormal lysosomal accumulation of phospholipids and consistent with the appearance of drug-induced phospholipidosis in people and other animals. The objective of this study was to compare concentrations of urine di-docosahexaenoyl (22:6)-bis(monoacylglycerol)phosphate (BMP), a biomarker of drug-induced phospholipidosis, in dogs with DCM eating high-pulse (HP) diets, dogs with DCM eating low-pulse (LP) diets, and healthy controls (control-HP and control-LP).
Methods: In this cross-sectional study, voided urine was collected from client-owned dogs with DCM from September 2018 through March 2020.
Label-Free Screening of Drug-Induced Liver Injury Using Stimulated Raman Scattering Microscopy and Spectral Phasor Analysis.
Anal Chem
July 2024
Centre for Nanometrology, Department of Pure and Applied Chemistry, Technology and Innovation Centre, University of Strathclyde, Glasgow G1 1RD, U.K.
Article Synopsis
- Hepatic toxicity is a major reason for stopping clinical trials and withdrawing drugs, so it's crucial to detect drug-induced liver injury (DILI) for patient safety and drug effectiveness.
- This study introduces hyperspectral stimulated Raman scattering (SRS) microscopy, a new method to distinguish between two types of DILI: drug-induced steatosis (DIS) and drug-induced phospholipidosis (DIPL), by analyzing lipid levels in cells.
- The researchers created a set of alkyne-tagged propranolol analogues with different DILI effects, and their hyperspectral SRS technique successfully verified traditional fluorescence assays, making it a promising tool for evaluating liver toxicity early in drug development.
The role of lysosomal phospholipase A2 in the catabolism of bis(monoacylglycerol)phosphate and association with phospholipidosis.
J Lipid Res
July 2024
Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. Electronic address:
Bis(monoacylglycerol)phosphate (BMP) is an acidic glycerophospholipid localized to late endosomes and lysosomes. However, the metabolism of BMP is poorly understood. Because many drugs that cause phospholipidosis inhibit lysosomal phospholipase A2 (LPLA2, PLA2G15, LYPLA3) activity, we investigated whether this enzyme has a role in BMPcatabolism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!